ArticleWorld journal of gastroenterology2010
Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran.
Article in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Trial
- High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy.Medicine · 2016Trial
- Antibiotic Resistance Identification Among the Patients withMiddle East journal of digestive diseases · 2025Article
- Detection ofArchives of Razi Institute · 2023Article
- The efficacy and safety of furazolidone-bismuth quadruple therapy forGastroenterology and hepatology from bed to bench · 2022Article
- Phenotypic analysis of antibiotic resistance and genotypic study of theAntimicrobial resistance and infection control · 2018Article
- Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.Digestive diseases and sciences · 2017Review
- Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment forThe American journal of tropical medicine and hygiene · 2017Article
- Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens forMiddle East journal of digestive diseases · 2017Article
- Evaluation of Clarithromycin Resistance Among Iranian Helicobacter pylori Isolates by E-Test and Real-Time Polymerase Chain Reaction Methods.Jundishapur journal of microbiology · 2016Article
- Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.World journal of methodology · 2015Review
- How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.Gastroenterology clinics of North America · 2015Review
- Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.Molecules (Basel, Switzerland) · 2015Review
- Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial.Middle East journal of digestive diseases · 2015Article
- Helicobacter pylori in Iran: A systematic review on the antibiotic resistance.Iranian journal of basic medical sciences · 2015Review
- Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2013Article
- Genetic Analysis of cagA and vacA Genes in Helicobacter Pylori Isolates and Their Relationship with Gastroduodenal Diseases in the West of Iran.Iranian Red Crescent medical journal · 2013Article
- Validation of an in-house made rapid urease test kit against the commercial CLO-test in detecting Helicobacter pylori infection in the patients with gastric disorders.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2012Article
- Helicobacter pylori in Iran: A systematic review on the association of genotypes and gastroduodenal diseases.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2012Article
- Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran.Journal of microbiology (Seoul, Korea) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo improve our understanding of Iranian regional variation in Helicobacter pylori (H. pylori) antibiotic resistance rates to find the best antibiotic therapy for eradication of H. pylori infections.
methodsA total of 266 patients undergoing endoscopy in Shiraz, Southern Iran, were included in this study. H. pylori strains were isolated from antral biopsies by culture and confirmed by the rapid urease-test and gram staining. Antibiotic susceptibility of H. pylori isolates was determined by E-test.
resultsA total of 121 H. pylori strains were isolated, 50 from male and 71 from female patients. Data showed that 44% (n = 53), 20% (n = 24), 5% (n = 6), and 3% (n = 4) of all strains were resistant to the antibiotics metronidazole, amoxicillin, clarithromycin, and tetracycline, respectively. When the antibiotics were considered together we found 11 sensitivity patterns for the strains. Resistance to metronidazole was significantly higher in female than in male patients (P < 0.05). In about 71% of the metronidazole-resistant isolates, the minimum inhibitory concentrations (MICs) exceeded 256 μg/mL.
conclusionWe found a moderate rate of primary resistance to metronidazole. However, a high MIC (> 256 mg/L) which was found in 71% of the isolates is considerable. In the case of amoxicillin, an increased resistance rate of 20% is worrying. Resistance to clarithromycin and tetracycline is also emerging among the H. pylori strains in our region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.